July, 2010 - “ORCA Therapeutics B.V. a biopharmaceutical company in the field of virotherapy, today announced that it obtained an exclusive license from VCN Biosciences L.S. in Gelida (Barcelona), Spain, to their T1 oncolytic adenovirus technology for the treatment of cancer.
This license allows ORCA Therapeutics to develop and commercialize new next generation oncolytic adenoviruses with increased oncolytic potency. “We are very excited to have in licensed this technology from VCN Biosciences. Securing this intellectual property will enhance our competitive position in virotherapy” said Dr. Janneke Meulenberg, CEO of ORCA Therapeutics B.V. This license from VCN Biosciences offers us a unique opportunity to combine our oncolytic adenovirus technology and know-how with the T1 technology to develop more effective oncolytic adenoviruses for treatment of cancer” “We have been looking for a company whose intellectual property could be combined with the T1 technology to move it towards clinical application. ORCA is the ideal partner. A preceding scientific collaboration between founder scientist of ORCA and us has led to present agreement that prioritizes clinical translation and gives both partners a good opportunity to grow”, said Dr. Manel Cascallo, COO of VCN Biosciences.